Table 1.
Characteristics of patients
| Variable | HRM | Non-HRM | p-value |
|---|---|---|---|
| Number of patients | (17%)125 | (83%) 590 | |
| Median age at transplant, years (range) | 58 (33–72) | 58 (28–76) | 0.91 |
| Age >65 | 69 (55) | 338 (57) | 0.67 |
| Male Gender | |||
| Race | 0.55 | ||
| White | 98 (78) | 460 (78) | |
| Black | 21 (17) | 110 (19) | |
| Others1 | 5 (4) | 12 (2) | |
| Unknown | 1 (<1) | 8 (1) | |
| Karnofsky Score, < 90% | 56 (45) | 222 (38) | 0.15 |
| HCT-CI score, >3 | 19 (15) | 92 (16) | 0.62 |
| Disease-related | |||
| Cytogenetic abnormality (conventional or FISH) |
|||
| High Risk | |||
| t(4;14) only | 28 (22) | -- | |
| t(14;16) only | 5 (4) | -- | |
| del17p only | 28 (22) | -- | |
| Hypodiploid only | 12 (10) | -- | |
| Chromosome 1 abnormalities only | 25 (20) | -- | |
| ≥2 High risks | 27 (22) | -- | |
| ISS/Durie-Salmon Stage III | 54 (43) | 167 (28) | 0.003 |
| Beta-2 microglobulin level at diagnosis, ≥3.5 mg/l |
73 (58) | 226 (38) | <0.001 |
| Serum albumin at diagnosis, < 3.5 g/dl | 53 (42) | 175 (30) | 0.02 |
| Hemoglobin at diagnosis, g/dl | |||
| N Evaluable | 121 | 562 | |
| Median (range) | 10 (3–17) | 11 (1–18) | <0.001 |
| Serum creatinine ≥ 2 mg/dl at diagnosis | 10 (3–17) | 11 (1–18) | 0.34 |
| Treatment-related | |||
| Lines of chemotherapy | 0.81 | ||
| 1 | 102 (82) | 476 (81) | |
| 2 | 23 (18) | 114 (19) | |
| Pre-Transplant Chemotherapy | <0.001 | ||
| IMID + Bort +/− Steroids | 70 (56) | 254 (43) | |
| IMID +/− Steroids | 15 (12) | 185 (31) | |
| Bort +/− Cytoxan +/− Steroids | 27 (22) | 88 (15) | |
| Others2 | 5 (4) | 17 (3) | |
| Disease status at transplant | 0.11 | ||
| CR | 17 (14) | 92 (16) | |
| VGPR | 44 (35) | 164 (28) | |
| PR | 53 (42) | 290 (49) | |
| SD | 4 (3) | 30 (5) | |
| Rel/prog | 7 (6) | 14 (2) | |
| Time from diagnosis to transplant | 0.84 | ||
| < 6 months | 54 (43) | 249 (42) | |
| 6 – 12 months | 71 (57) | 341 (58) | |
| Year of transplant | 0.01 | ||
| 2008 | 25 (20) | 213 (36) | |
| 2009 | 18 (14) | 68 (12) | |
| 2010 | 18 (14) | 79 (13) | |
| 2011 | 36 (29) | 129 (22) | |
| 2012 | 28 (22) | 101 (17) | |
| Post-transplant therapy | 0.004 | ||
| Lenalidomide+Bortezomib+/−Steroid | 33 (26) | 72 (12) | |
| Lenalidomide+/− Steroid | 37 (30) | 218 (37) | |
| Bortezomib +/− Steroid | 3 (2) | 12 (2) | |
| Thalidomide +/− Steroid | 3 (2) | 9 (2) | |
| Others | 0 | 4 (<1) | |
| No post-transplant therapy | 36 (29) | 200 (34) | |
| Unknown | 13 (10) | 75 (13) | |
| Median follow-up of survivors (range), months |
36 (3–78) | 44 (3–83) |